School Of Basic And Applied Sciences
Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/17
Browse
4 results
Search Results
Item Role of prostate cancer stem-like cells in the development of antiandrogen resistance(OAE Publishing Inc., 2022-06-09T00:00:00) Kushwaha, Prem Prakash; Verma, Shiv; Kumar, Shashank; Gupta, SanjayAndrogen deprivation therapy (ADT) is the standard of care treatment for advance stage prostate cancer. Treatment with ADT develops resistance in multiple ways leading to the development of castration-resistant prostate cancer (CRPC). Present research establishes that prostate cancer stem-like cells (CSCs) play a central role in the development of treatment resistance followed by disease progression. Prostate CSCs are capable of self-renewal, differentiation, and regenerating tumor heterogeneity. The stemness properties in prostate CSCs arise due to various factors such as androgen receptor mutation and variants, epigenetic and genetic modifications leading to alteration in the tumor microenvironment, changes in ATP-binding cassette (ABC) transporters, and adaptations in molecular signaling pathways. ADT reprograms prostate tumor cellular machinery leading to the expression of various stem cell markers such as Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1), Prominin 1 (PROM1/CD133), Indian blood group (CD44), SRY-Box Transcription Factor 2 (Sox2), POU Class 5 Homeobox 1(POU5F1/Oct4), Nanog and ABC transporters. These markers indicate enhanced self-renewal and stemness stimulating CRPC evolution, metastatic colonization, and resistance to antiandrogens. In this review, we discuss the role of ADT in prostate CSCs differentiation and acquisition of CRPC, their isolation, identification and characterization, as well as the factors and pathways contributing to CSCs expansion and therapeutic opportunities. � The Author(s) 2022.Item Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer(Elsevier Ireland Ltd, 2021-02-07T00:00:00) Kumar, Shashank; Prajapati, Kumari Sunita; Singh, Atul Kumar; Kushwaha, Prem Prakash; Shuaib, Mohd; Gupta, SanjayThe human genome transcribe an array of RNAs that do not encode proteins and may act as mediators in the regulation of gene expression. Long non-coding RNAs (lncRNAs) are a group of non-coding RNAs consisting of more than 200 nucleotides of RNA transcripts that play important role in tumor development. Numerous lncRNAs have been characterized as functional transcripts associated with several biological processes and pathologic stages. Although the biological function and molecular mechanisms of lncRNAs remains to be explored, recent studies demonstrate aberrant expression of several lncRNAs linked with various human cancers. The present review summarizes the current knowledge of lncRNA expression patterns and mechanisms that contribute to carcinogenesis. In particular, we focus on lncRNAs regulating androgen receptor signaling pathways in prostate and breast cancer subtype having prognostic and therapeutic implications. � 2021 Elsevier B.V.Item Histopathological staging in putative prostate cancer tissues and reviewing litearture of correlation between prostate specific antigen levels and prostate cancer inci. 2012.(Central University of Punjab, 2012) Thakur, Shweta; Thakur, SanjeevProstate cancer (PCa) remains the most significant cause of cancer specific mortality in elderly men. Asymptomatic behavior, non-modifiable risk factors and metastatic nature is the main problem of PCa. It remains clinically silent and presents itself only at advanced stage. Thus, diagnosing PCa at an early stage can result in increased chances of better treatment and hence, increased survival rate. An accurate biomarker can detect the cancer at an early stage and hence, at curable stage. Clinical parameters can only suspect prostate cancer. Whereas, histopathological examination can establish definite diagnosis of PCa. Various histological patterns are associated with cancer aggressiveness. Therefore, better understanding of clinical relevance of these histopathological findings can help to evaluate a robust biomarker for early detection of PCa. Present study was divided into two parts. First part was aimed to study the histopathology of putative prostate cancer tissue specimens. In second part, the literature of association of pre-operative serum prostate specific antigen levels with cancer detection and aggressiveness was reviewed. Protocol for histopathology of prostate tissues was established. Results of histopathological findings in putative PCa specimens were evaluated. Prevalence of histological PCa was not found in putative PCa tissues. Image library of results of the study was prepared for future analysis. Review of literature of correlation of serum PSA levels with PCa incidence suggests that PSA screening for PCa is a two-sided debate. No doubt that PSA holds the probability of detecting early PCa before development of symptoms; certain v limitations are associated with it. First, it is not reported to be 100% accurate. Second, it generates false positive and false negative results. A false positive result leads to over-treatment whereas a false negative result generates false sense of security against PCa in patient, both affects quality of life. Another main concern with PSA screening is its inability to differentiate between indolent and aggressive cancer. Therefore; accurate and economical molecular biomarkers for early detection and distinction of indolent versus aggressive cancer are urgently required. Until such biomarkers are developed and more convincing evidences regarding efficacy of PSA screening becomes available, research should focus on improving the diagnostic clinical utility of PSA by utilizing novel PSA isoforms. Identifying and validating correlation of serum PSA with tissue PSA and histological grade would be beneficial in terms of requirement of less invasive diagnostic methods to be used to measure PSA expression level as well as to confirm PCa. Future research may focus on evaluating the histological expression of other putative biomarkers and comparative serum proteomic profiling in different PCa stages.Item Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents.(Elsevier, 2015) Joshi,Gaurav; Singh, Pankaj Kumar; Negi, Arvind; Rana, Anil; Singh, Sandeep; Kumar, RajCancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer is one of the most encountered malignancies among men. Globally, it is the sixth leading cause of cancer-related death in men. Prostate cancer is more prevalent in the developed world and is increasing at alarming rates in the developing countries. Prostate cancer is mostly a very sluggish progressing disease, caused by the overproduction of steroidal hormones like dihydrotestosterone or due to over-expression of enzymes such as 5-α-reductase. Various studies have revealed that growth factors play a crucial role in the progression of prostate cancer as they act either by directly elevating the level of steroidal hormones or upregulating enzyme efficacy by the active feedback mechanism. Presently, treatment options for prostate cancer include radiotherapy, surgery and chemotherapy. If treatment is done with prevailing traditional chemotherapy; it leads to resistance and development of androgen-independent prostate cancer that further complicates the situation with no cure option left. The current review article is an attempt to cover and establish an understanding of some major signalling pathways intervened through survival factors (IGF-1R), growth factors (TGF-α, EGF), Wnt, Hedgehog, interleukin, cytokinins and death factor receptor which are frequently dysregulated in prostate cancer. This will enable the researchers to design and develop better therapeutic strategies targeting growth factors and their cross talks mediated prostate cancer cell signalling.